Cargando…
Targeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility
Denosumab is a breakthrough biological drug approved by the Food and Drug Administration and European Medicines Agency for the treatment of osteoporosis in 2010. It is a fully human monoclonal antireceptor activator of nuclear factor kappa-B ligand antibody, which inhibits the activity of osteoclast...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3383338/ https://www.ncbi.nlm.nih.gov/pubmed/22745560 http://dx.doi.org/10.2147/TCRM.S7688 |